Business Description
Navidea Biopharmaceuticals, founded in 1983 and based in Dublin, Ohio, works to develop medical tools that help detect and treat diseases involving the immune system. Its core technology targets specific receptors on immune cells called macrophages, enabling more precise imaging of conditions such as rheumatoid arthritis, cardiovascular disease, and tuberculosis. The company has several drug candidates in active clinical trials, with some reaching Phase III testing. In October 2025, Navidea filed for Chapter 11 bankruptcy protection in Delaware federal court.
